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ABSTRACT Tuberculosis (TB), which is caused by Mycobacterium tuberculosis, re-
mains a leading killer worldwide, and disease control is hampered by the ineffective
control of persistent infections. Substitution of moxiﬂoxacin for isoniazid or etham-
butol in standard anti-TB regimens reduces the treatment duration and relapse rates
in animal studies, and 4-month regimens were not noninferior in clinical trials.
Resuscitation-promoting factor (RPF)-dependent bacilli have recently been impli-
cated in M. tuberculosis persistence. We aimed to investigate the therapeutic effects
of the substitution of moxiﬂoxacin for a drug used in the standard drug regimen in
eradicating CFU count-positive and RPF-dependent persistent M. tuberculosis using
the Cornell murine model. M. tuberculosis-infected mice were treated with regimens
in which either isoniazid or ethambutol was replaced by moxiﬂoxacin in the stan-
dard regimen. The efﬁcacy of the regimens for bacterial CFU count elimination and
removal of persistent tubercle bacilli, evaluated using culture ﬁltrate (CF) derived
from M. tuberculosis strain H37Rv, was compared to that of the standard regimen.
We also measured disease relapse rates. The regimen in which moxiﬂoxacin replaced
isoniazid achieved total organ CFU count clearance at 11 weeks posttreatment,
which was faster than that by the standard regimen (14 weeks), and showed a 34%
lower relapse rate. The regimen in which moxiﬂoxacin replaced ethambutol was sim-
ilar to standard regimens in these regards. Importantly, neither the regimen in which
moxiﬂoxacin replaced isoniazid or ethambutol nor the standard regimen could re-
move CF-dependent persistent bacilli. The ﬁnding of CF-dependent persistent M. tu-
berculosis in TB treatment requires conﬁrmation in human studies and has impli-
cations for future drug design, testing, and clinical applications.
KEYWORDS Mycobacterium tuberculosis, moxiﬂoxacin, resuscitation-promoting
factors, Cornell mouse model
Tuberculosis (TB), which is caused by Mycobacterium tuberculosis, remains a leadingcause of mortality worldwide (1). Current combination antimicrobial regimens
require a prolonged 6-month treatment period. This long regimen leads to poor patient
compliance, which gives rise to the emergence of drug resistance and high relapse
rates (2). Substitution of moxiﬂoxacin (an 8-methoxy ﬂuoroquinolone) for drugs in the
contemporary anti-TB regimen has shown promise for improving treatment efﬁcacy (3,
4). In vivo, replacement of isoniazid with moxiﬂoxacin led to a shortened treatment
duration (5, 6), reduced relapse rates (6, 7), and favorable outcomes (8) in BALB/c and
granuloma-forming C3HeB/FeJ mice. In the recent REMoxTB trial, shorter (4-month)
moxiﬂoxacin replacement regimens (in which moxiﬂoxacin was substituted for either
isoniazid or ethambutol) in human clinical trials failed to achieve noninferiority com-
pared to standard regimens (3, 4), mainly due to higher relapse rates (3, 4, 9). Persistent
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bacteria that are tolerant to drug therapy may be implicated in the higher disease
relapse rates (9).
M. tuberculosis persistence is the single most important hurdle hampering effective
TB disease control (10). M. tuberculosis has the ability to survive in a dormant, nonmul-
tiplying, and persistent state (11–14). These persistent bacteria do not grow on solid or
liquid media and are undetectable using conventional diagnostic methods; however,
they can be resuscitated using resuscitation-promoting factors (RPF), which are present in
theM. tuberculosis culture supernatant (15). Recently, we found that, using a culture ﬁltrate
(CF) containing RPF (15), we could induce persistent bacteria to recommence multiplica-
tion, rendering them detectable oncemore in mice (16–18). Moreover, these tubercle bacilli
resuscitated with CF could be completely eliminated using high-dose rifampin regimens,
shortening the treatment duration with no disease relapses (16, 18).
In this study, we used the Cornell mouse model (19, 20) to investigate the thera-
peutic impact of moxiﬂoxacin replacement of a drug in the standard anti-TB regimen
against both CFU count-positive and CF-dependent bacteria. We compared the regi-
mens in which either isoniazid or ethambutol was replaced by moxiﬂoxacin to the
standard regimen by measurement of the elimination rates of CFU counts, the presence
of CF-dependent M. tuberculosis in mouse organs, and disease relapse rates.
RESULTS
Treatment with moxiﬂoxacin-containing regimens in the Cornell mouse model.
In the Cornell mouse model, after 3 weeks of infection, the mean CFU counts in the
organs reached log 7.54 in lungs and 6.99 in spleens (Table 1).
When we investigated the substitution of moxiﬂoxacin for either isoniazid or
ethambutol in the current drug regimen on the rate of bacterial CFU count elimination,
we found that the early bactericidal activities were similar among the three drug
treatment regimens, which were 99% kill at 2.2 weeks for the regimen in which
moxiﬂoxacin replaced isoniazid (which contained rifampin, moxiﬂoxacin, pyrazinamide,
and ethambutol [the RMZE regimen]), 2.7 weeks for the standard regimen (which
contained rifampin, isoniazid, pyrazinamide, and ethambutol [the RHZE regimen]), and
3 weeks for the regimen in which moxiﬂoxacin replaced ethambutol (which contained
rifampin, isoniazid, pyrazinamide, and moxiﬂoxacin [the RHZM regimen]). Treatment
with the RMZE regimen increased the rate of bacterial elimination, showing undetect-
able CFU counts at 11 weeks, whereas undetectable CFU counts were seen at 14 weeks
for the standard regimen and the regimen in which moxiﬂoxacin replaced ethambutol
(Table 1).
These observations coincided with the bactericidal activities assessed using the
monoexponential bacterial elimination rate constants (Fig. 1 and Table 2), where the
exponential rate constants (logarithmic base 10) for net bacterial elimination during
treatment (knet_with_drug) for the standard regimen, the regimen in which moxiﬂoxacin
replaced ethambutol, and the regimen in which moxiﬂoxacin replaced isoniazid were
0.46, 0.50, and 0.65, respectively, in lungs and 0.46, 0.46, and 0.60, respec-
TABLE 1 Organ CFU counts before and after treatment with experimental regimens
Time of infection
or treatmenta
Mean no. of log CFU per lung  SD Mean no. of log CFU per spleen  SD
Control
RHZE
regimen
RHZM
regimen
RMZE
regimen Control
RHZE
regimen
RHZM
regimen
RMZE
regimen
Day 0 4.80 0.14 5.29 0.03
Day 21 7.54 0.03 6.99 0.06
2 wk 6.09 0.03 5.92 0.14 5.70 0.12 5.43 0.08 5.54 0.12 4.77 0.10
4 wk 4.80 0.07 4.52 0.28 3.61 0.16 4.05 0.02 4.49 0.08 3.31 0.21
6 wk 4.08 0.11 4.00 0.09 2.53 0.29 3.49 0.16 3.81 0.06 2.27 0.20
8 wk 3.00 0 3.25 0.48 2.00 0 2.44 0.22 3.24 0.13 1.57 0.20
11 wkb 2.00 0 2.00 0 0 1.19 0.29 2.00 0 0
14 wkb 0 0 0 0 0 0
aDay 0 and day 21 represent 2 h and 21 days postinfection, respectively. Times in weeks represent times posttreatment.
bCFU counts were derived from one-third of the tissue homogenate, and the limit of detection was 3 CFU/organ.
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tively, in spleens (Table 2). The higher that the absolute value of this elimination rate
constant is (i.e., the steeper that the slope of the elimination on the logarithmic scale
with units of week1 is), the quicker that the exponential elimination rate of CFU counts
in the organs is. These values therefore indicate that, compared to the standard
therapy, substitution of moxiﬂoxacin for isoniazid gives a signiﬁcant increase in bac-
terial elimination in both lungs and spleens, while substitution of moxiﬂoxacin for
ethambutol makes a statistically indistinguishable difference.
In the CFU count-free organs, no tubercle bacilli were recovered, which was deter-
mined by negative cultures of the organ homogenates in selective Kirchner broth for
4 weeks followed by growth on Löwenstein-Jensen medium.
Posttreatment level of CF-resuscitated MPN in the Cornell mouse model. In
order to investigate the effect of the moxiﬂoxacin-containing regimens on the post-
treatment level of persistent bacilli detected through CF-induced resuscitation, lung
and spleen homogenates obtained during the weeks of treatment when CFU counts of
zero were achieved by each of the regimens were incubated with culture ﬁltrates. As
shown in Table 3, after 14 weeks of treatment with the RHZE and RHZM regimens, high
levels of CF-resuscitated bacilli remained in both the lungs and spleens. For the
treatment with the RMZE regimen, at 11 weeks posttreatment, although the CFU
counts were zero, there averaged a most probable number (MPN) of CF-resuscitated
bacilli per lung and spleen of 2.96 and 3.01 logs, respectively. At 14 weeks of treatment,
there was still a MPN of 2 logs of bacilli present (Table 3). The numbers of CF-dependent
bacteria among the three treatment groups were not signiﬁcantly different at 14 weeks
posttreatment (P  0.05, n  8).
FIG 1 Proﬁles of M. tuberculosis H37Rv after treatment with the RHZE, RMZE, and RHZM regimens in the Cornell mouse
model. (A) Elimination of CFU counts in lungs. (B) Elimination of CFU counts in spleens. Solid arrows, start of treatment at
3 weeks of postinfection; empty arrows, start of steroid treatment after the termination of 14 weeks of therapy; Obs,
observed.
TABLE 2 Elimination rate constants for different treatment groups
Treatment regimen
Elimination rate constant (wk1)a
Lungsb Spleensc
Alpha % RSE Alpha % RSE
RHZE 0.46 3.20 0.46 4.76
RHZM 0.50 8.57 0.46 6.54
RMZE 0.65 10.96 0.57 6.40
aThe elimination rate constant is equivalent to knet_with_drug. RSE, relative standard error.
bP  0.008 for the RMZE versus RHZE regimen, P  0.065 for the RMZE versus RHZM regimen, and P 
0.384 for the RHZE versus RHZM regimen. A P value of 0.017 was signiﬁcant at the 0.05 level after
Bonferroni correction for 3 pairwise comparisons.
cP  0.018 for the RMZE versus RHZE regimen, P  0.011 for the RMZE versus RHZM regimen, and P 
0.943 for the RHZE versus RHZM regimen. A P value of 0.017 was signiﬁcant at the 0.05 level after
Bonferroni correction for 3 pairwise comparisons.
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Relapse rates after treatment with the moxiﬂoxacin-containing regimens in the
Cornell mouse model. After 8 weeks of high-dosage steroid immunosuppression, the
disease relapse rates in mice treated with one of the three drug regimens were
determined according to the percentage of mice that developed M. tuberculosis-
positive cultures (CFU counts) of lung or spleen tissues, or both. As shown in Table 4,
treatment with the standard RHZE regimen gave rise to positive organs in 19 out of 21
mice (90% relapse rate), and that with the RHZM regimen led to a 95% relapse rate after
14 weeks of treatment. In contrast, treatment with the RMZE regimen resulted in a 59%
relapse rate (P  0.03 versus the RHZE regimen and P  0.009 versus the RHZM
regimen; a P value of0.017 was signiﬁcant at the 0.05 level after Bonferroni correction
for 3 pairwise comparisons).
We also measured, using culture ﬁltrates, CF-dependent bacilli in the organs which
were CFU count negative after 8 weeks of steroid treatment. As shown in Table 4, the
negative organs in each treatment group contained high numbers of CF-dependent
cells. The average values were MPN of 3.3, 3.51, and 3.05 logs per organ in the groups
receiving the RHZE, RHZM, and RMZE regimens, respectively.
DISCUSSION
This is the ﬁrst study to use the reliable Cornell mouse model to characterize the
therapeutic efﬁcacy of moxiﬂoxacin replacement in vivo against CF-dependent M.
tuberculosis persistent cells. Compared to the standard anti-TB regimen, we found that
moxiﬂoxacin replacement of isoniazid (i) failed to remove CF-dependent bacilli, despite
producing (ii) higher organ CFU count elimination rates and (iii) lower disease relapse
rates. In contrast, moxiﬂoxacin replacement of ethambutol failed to demonstrate any
therapeutic beneﬁts compared to the standard regimen. These results of CF resuscita-
tion need to be conﬁrmed in human studies but may provide a novel mechanistic
explanation for the results of moxiﬂoxacin replacement regimens in clinical trials. The
ﬁndings in this study also have important future implications for novel anti-TB drug
design, diagnostic testing, and clinical applications.
The treatment regimens in which moxiﬂoxacin replaced the drugs used in
the standard regimen are ineffective against CF-dependent tubercle bacilli. The
TABLE 3MPN of M. tuberculosis H37Rv in CFU count-negative mouse lungs and spleens after treatment with different drug regimensc
Treatment regimen
MPN/lunga MPN/spleenb
11 wk
95% conﬁdence
limits 14 wk
95% conﬁdence
limits 11 wk
95% conﬁdence
limits 14 wk
95% conﬁdence
limits
RHZE — 2.50 0.19 2.35–2.67 — 2.56 0.16 2.44–2.70
RHZM — 2.55 0.14 2.44–2.67 — 2.60 0.09 2.52–2.69
RMZE 2.96 0.15 2.86–3.08 2.30 0.23 2.15–2.50 3.01 0.14 2.92–3.11 2.35 0.16 2.27–2.45
aDetermined from the MPN of bacilli in the diluted lung homogenates (n  8) with the culture ﬁltrates.
bDetermined from the MPN of baclli in the diluted spleen homogenates (n  8) with the culture ﬁltrates.
cFor a CFU count of 0, organs showed no growth in Kirchner liquid medium, followed by inoculation on Löwenstein-Jensen slopes. Broth counts were derived from
one-third of the tissue homogenate and calculated to represent the MPN of bacilli in the entire organ. The limit of detection was 30 MPN/organ. —, the colony
count was positive, and MPN counts were not performed for the organs. The limit of detection was 3 CFU/organ.
TABLE 4 Relapse rates of mice after treatment with different drug regimensb
Treatment
regimen
No. of mice with positive culture results for:
Relapse rate
pn/N (%)a
MPN of CFU
count-negative
organs
Spleen
only
Lung
only
Both
organs
Neither
organs Total
RHZE 3 0 16 2 21 19/21 (90) 3.30 0.13
RHZM 5 2 13 1 21 20/21 (95) 3.51 0.11
RMZE 4 5 4 9 22 13/22 (59) 3.05 0.18
aRelapse rates include all lungs or spleens or both organs positive for bacilli. N, total number of mice; pn,
number of mice with CFU count-positive organs.
bP  0.03 for the RMZE versus RHZE regimen, P  0.009 for the RMZE versus RHZM regimen, and P  1 for
the RHZE versus RHZM regimen. A P value of 0.017 was signiﬁcant at the 0.05 level after Bonferroni
correction for 3 pairwise comparisons.
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greater therapeutic efﬁcacy and lower relapse rates achieved in this study with the
regimen in which moxiﬂoxacin replaced isoniazid than with the standard regimen are
consistent with previous reports (5–8). De Groote et al. demonstrated that replacement
of isoniazid by moxiﬂoxacin in the standard regimen gave rise to a 63% disease relapse
rate (6). In other studies, Nuermberger and colleagues showed that the same drug
regimen produced a lower disease relapse rate of 33.3% (7). Late studies using two
pathologically distinct murine tuberculosis models demonstrated very similar low
disease relapse rates (8). Our study conﬁrmed this interesting observation, showing a
56% relapse rate, indicating the consistency of the drug regimen in different mouse
models.
The underlying mechanisms that moxiﬂoxacin replacing isoniazid was more efﬁca-
cious than the standard or moxiﬂoxacin replacing ethambutol regimens were un-
known. It has been shown previously that when mice were treated with rifampin-
isoniazid-pyrazinamide, rifampin-isoniazid, or rifampin-pyrazinamide for 6 months, the
rifampin-pyrazinamide-treated group demonstrated signiﬁcantly lower relapse rates
than the other two groups treated with regimens containing isoniazid (21), suggesting
that isoniazid antagonized the actions of rifampin and pyrazinamide (21). It is possible
that the replacement of isoniazid with moxiﬂoxacin eliminated the antagonistic drug
interaction, leading to the rapid organ CFU count clearance in mice.
The use of CFU counts as an endpoint reﬂects the clinical observations in patients
to a large degree, which is related to clinical endpoints, such as sputum culture
conversion in patients (3, 22, 23). The improved efﬁcacy of the regimen in which
moxiﬂoxacin replaced isoniazid compared to that of the standard regimen reﬂected the
clinical outcome in patients to some extent; for example, the regimen in which
moxiﬂoxacin was substituted for isoniazid showed effective bactericidal activity and
was able to kill CFU count-positive bacilli faster than the standard regimen, leading to
a higher sputum culture conversion rate in humans (3, 22, 23).
Despite the improved performance, the regimen in which moxiﬂoxacin replaced
isoniazid was ineffective against CF-dependent bacterial cells, which has not been
demonstrated previously. At 11 weeks and the end of antibiotic therapy, despite the
elimination of CFU counts indicating positivity for bacilli, a considerable MPN of
CF-dependent bacilli remained in all the mice, and the number was similar to that in
mice treated with the standard drug regimen or the regimen in which moxiﬂoxacin
replaced ethambutol. This indicates that although the regimen in which moxiﬂoxacin
replaced isoniazid was more bactericidal than the standard regimen, the drug regimen
failed to show improved sterilizing activity against persistent bacteria. After 8 weeks of
immunosuppression with steroids, 90% of mice treated with the standard regimen and
95% of mice treated with the regimen in which moxiﬂoxacin replaced ethambutol that
had CF-dependent bacterial cells became CFU count positive again. This high disease
relapse rate can be feasibly explained only by the reactivation of CF-dependent
bacterial cells since the mice had a CFU count of 0 before immunosuppression. In
addition to a lower relapse rate, mice treated with the regimen in which moxiﬂoxacin
replaced isoniazid contained MPN counts in their negative organs similar to those in
the other two groups. This indicates that certain drug regimens, such as the regimen
in which moxiﬂoxacin replaced isoniazid, may induce heterogeneously more diverse
bacterial populations; therefore, not all CF-responding bacteria regained their ability to
form colonies on agar plates at the time that we determined relapse, showing a lower
disease relapse rate. Further studies on the induction of the heterogeneity of bacterial
populations using different anti-TB drug regimens are warranted.
Clinical trials and animal studies. (i) Different test beds but the same mecha-
nism. None of the two phase III clinical trials in which moxiﬂoxacin replaced a drug in
the standard regimen demonstrated the noninferiority of those regimens to the
standard regimen in terms of treatment duration and disease relapses (3, 4); the
underlying mechanism is unclear. An important ﬁnding of the REMoxTB trial is that a
proportion of patients showed sputum conversion quickly but continued to relapse
after treatment with all three drug regimens (9). Our experiments suggest that the high
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relapse rates may have been due to CF-dependent bacilli (9), which, until now, have
remained undetectable using conventional culture methods, including those used in
the clinical trials (3, 4, 9). Persistent bacteria are established causes of prolonged
chemotherapy and disease relapse (10). It has been repeatedly shown that, in the
Cornell mouse model, the high relapse rate after treatment with the standard drug
regimen was due to the presence of CF-dependent persistent bacteria (16, 17). Re-
cently, we showed that drug regimens containing high doses of rifampin (30 mg/kg of
body weight or higher) could eliminate CF-dependent persistent bacilli, which led to a
shortening of the treatment duration from 14 weeks to just 6 weeks, without disease
relapses (16, 18). The lesson learned from the REMoxTB trial is that more rapid culture
conversion in the short moxiﬂoxacin-containing regimens may not allow for shortened
regimens due to the presence of persistent bacteria (9). A previous study also showed
that the early bactericidal activities of certain novel drug regimens were not necessarily
predictive of any sterilizing effects (24). This may be attributed to the inability of the
drug regimens to eliminate the persistent bacilli which were undetectable using
traditional microbiological methods. Therefore, in addition to conventional microbio-
logical methods, evaluation of anti-TB regimens by assessing their efﬁcacies in elimi-
nating RPF-dependent M. tuberculosis is important for providing a comprehensive
proﬁle of novel drug regimens before proceeding to human clinical trials. The com-
bined data sets on CFU counts, growth in broth, and persister counts will strengthen
any claims to be made about a regimen, which will ultimately increase the conﬁdence
of advancing it into trials with humans.
(ii) Different test beds and important considerations. The interpretation of the
results obtained with the moxiﬂoxacin replacement regimens in mice compared with
interpretation of the results of clinical trials requires careful consideration. In the
previous animal studies, for example, the burden of persistent bacteria was not
detected or assessed (5, 7) largely due to the undetectable feature of the persisters (16,
17). Importantly, there are clear differences in the pathophysiology of TB between
humans and mice. Patients with active TB have persisters residing in a milieu of
different pathogenic sites, including necrotic/caseating lesions, central liquefactive
lesions, open cavities, and closed ﬁbrotic granulomas (25, 26). Indeed, a patient may
develop a combination of these lesions over time (10). Consequently, these heteroge-
neous persistent bacteria coexist with fast-growing bacteria at the time of commence-
ment of antibiotic treatment (10). In contrast, mice do not form granuloma structures
after M. tuberculosis infection (25), and persistent bacteria are generally low in absolute
number (similar to the CFU counts) at the beginning of treatment (16). In addition, an
important study has shown that moxiﬂoxacin does not diffuse into caseating lesions,
which may also lead to reduced sterilizing activities against persisters in human TB (27).
The treatment of M. tuberculosis persisters is complex, and future clinical trials will
require careful consideration of the results of mechanistic in vivo studies, which can
elucidate further insights into potential therapeutic targets. The study reported here
represents an important step in the right direction by showing that RPF-dependent
persisters may be a novel and important clinical therapeutic target. In conclusion, the
regimens in which moxiﬂoxacin was substituted for the antibiotics used in contempo-
rary drug regimens were ineffective against resuscitation-promoting factor-dependent
persistent M. tuberculosis, despite having favorable therapeutic efﬁcacy against actively
multiplying bacteria in vivo.
MATERIALS AND METHODS
Bacterium and growth conditions. M. tuberculosis strain H37Rv was passaged in mice and grown
in 7H9 medium that contained 0.05% Tween 80 and that was supplemented with 10% albumin-dextrose-
catalase complex (ADC; Becton, Dickinson, UK) at 37°C without disturbance for 15 days. The culture was
stored at 70°C for subsequent animal infection. To determine the viable counts prior to infection, CFU
counts were performed prior to freezing and once again after thawing. Counting of the number of CFU
was carried out by plating serial 10-fold dilutions of the cultures on 7H11 agar medium supplemented
with oleic-albumin-dextrose-catalase complex (OADC; Becton, Dickinson, UK). Colonies were counted
after incubation of the plates at 37°C for 3 to 4 weeks. Viability was expressed as the number of log CFU
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per milliliter. The cultures were subsequently diluted in phosphate-buffered saline and used for inocu-
lations in mice.
Cornell mouse model. The substitution of moxiﬂoxacin for either the isoniazid or ethambutol used
in the standard anti-TB drug regimen with rifampin and pyrazinamide was tested using the Cornell
mouse model (19, 20). The model was conducted using the experimental design and procedure
described previously (17).
Female BALB/c mice (6 to 8 weeks old; Harlan UK Ltd.) were infected intravenously via the tail vein
with 1.2  105 CFU of mouse-passaged M. tuberculosis strain H37Rv per mouse as described previously
(16, 17, 20). The animal husbandry guidelines and all animal experiments were performed according to
the Animals Scientiﬁc Procedures Act, 1986 (an Act of the Parliament of the United Kingdom 1986 c. 14;
Home Ofﬁce Project license number 70/7077), with approval from the St. George’s, University of London,
ethics committee.
As shown in Table 5, the control group consisted of 8 infected and untreated mice. The treatment
groups each contained 54 mice which were treated orally (0.2 ml) with the RHZE, RHZM, or RMZE
regimen 5 days per week for 14 weeks. The dosages for the drugs were 10 mg/kg for rifampin, 25 mg/kg
for isoniazid, 150 mg/kg for pyrazinamide, 100 mg/kg for ethambutol, and 100 mg/kg for moxiﬂoxacin.
Rifampin was administered 1 h before the other drugs to avoid drug-drug interactions.
For assessment of treatment efﬁcacy, a sample of 4 mice each was sacriﬁced at 2, 4, and 6 weeks of
treatment and a sample of 8 mice each was sacriﬁced at 8, 11, and 14 weeks of treatment (Table 5).
Mouse lungs and spleens were transferred into 2-ml tubes each containing 1 ml sterile distilled water and
2-mm-diameter glass beads, followed by homogenization using a reciprocal shaker (Thermo Hybaid Ltd.)
for 40 s at a speed of 6.5. The CFU counts from each lung and spleen were performed using serial
dilutions of the homogenates, which were plated on 7H11 agar plates.
At 11 and 14 weeks of treatment, the entire organ homogenates from the 8 mice were aliquoted
equally into three tubes, which were used for (i) determination of the CFU counts by plating out the
organ homogenate suspension on 6 selective 7H11 agar plates, (ii) culturing in 5 ml of selective Kirchner
liquid medium (28) with the addition of polymyxin B (200 U/ml), carbenicillin (100 mg/liter), trimethoprim
(20 mg/liter), and amphotericin B (10 mg/liter) (Selectatab; Mast Diagnostica GmbH) for 4 weeks and with
subsequent subculturing of the entire culture onto Löwenstein-Jensen slopes for a further 4 weeks, and
(iii) resuscitation of persistent bacteria with culture ﬁltrate. Kirchner liquid medium was used to isolate
different species of mycobacteria from human specimens. Mitchison et al. (28) showed that liquid
Kirchner medium, made selective by the addition of the antimicrobials, was more effective for the
isolation of mycobacteria than the other media tested. Culture-negative organs were deﬁned as organs
for which no colonies grew on 7H11 agar plates and for which there was no growth in selective Kirchner
liquid medium followed by inoculation on Löwenstein-Jensen slopes.
Immediately after the termination of 14 weeks of chemotherapy, the remaining mice were admin-
istered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 weeks to suppress host
immunity, followed by counting of the number of CFU from the lungs and spleens to determine disease
relapse.
Resuscitation of M. tuberculosis in mouse lungs and spleens. For resuscitation of M. tuberculosis
bacilli growing in mouse organs, culture ﬁltrates containing RPFs were used as described previously
(15–17).
M. tuberculosis H37Rv was grown in 7H9 medium without disturbance at 37°C for 15 to 20 days until
an optical density of 1 to 1.5 was reached. The culture supernatants were collected by centrifugation at
3,000  g for 15 min and sterilized by double ﬁltration through 0.2-m-pore-size ﬁlters (Sartorius). The
sterilized culture ﬁltrates were made selective by the addition of polymyxin B (200 U/ml), carbenicillin
(100 mg/liter), trimethoprim (20 mg/liter), and amphotericin B (10 mg/liter) (Selectatab; Mast Diagnostica
GmbH) and immediately used for broth dilution to count the most probable number (MPN) of the bacilli
(29).
Broth counting of the bacteria from lung and spleen tissue homogenates with culture ﬁltrates was
performed by the use of serial 10-fold dilutions, in which 0.5 ml of tissue homogenates was added to 4.5
ml of the culture ﬁltrates. At 10-day intervals over a 2-month period of incubation at 37°C, the broth
cultures were examined for visible turbidity changes. The growth of M. tuberculosis in turbid tubes was
conﬁrmed by the detection of the colonial morphology on 7H11 agar plates. The MPN of viable bacilli
TABLE 5Mouse tuberculosis experimental design
Treatment
regimena
No. of mice sacriﬁced at:
Totalb Day 0 Day 21 2 wk 4 wk 6 wk 8 wk 11 wk 14 wk 22 wkc
Control 8 4 4
RHZE 54 4 4 4 8 8 8 22
RHZM 54 4 4 4 8 8 8 22
RMZE 54 4 4 4 8 8 8 22
aMice were intravenously infected at day 0. Treatment commenced at 21 days. Dosages for each drug were
as follows: 10 mg/kg for rifampin, 25 mg/kg for isoniazid, 150 mg/kg for pyrazinamide, 100 mg/kg for
ethambutol, and 100 mg/kg for moxiﬂoxacin.
bAll mice, excluding the mice that died of natural causes during the course of treatment, were infected and
treated.
cAfter 8 weeks of hydrocortisone treatment that began after 14 weeks of treatment.
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was then estimated from the patterns of positive and negative tubes according to the method of the U.S.
Food and Drug Administration (29). The absence of microorganisms other than mycobacteria from turbid
tubes was conﬁrmed by plating of the contents of the tubes on blood agar medium (Oxoid) and
Sabouraud dextrose agar (Oxoid). In order to assess the sterility of culture ﬁltrates free of M. tuberculosis,
tubes containing culture ﬁltrates were incubated at 37°C for 2 months to ensure the absence of M.
tuberculosis in the culture ﬁltrates.
Statistical analysis. A simple model for monoexponential bacterial growth and elimination (17, 30)
was ﬁtted to the proﬁles of the number of CFU versus time obtained experimentally. As simultaneously
occurring exponential replication and death rates cannot be differentiated with this type of data, a knet
exponential rate constant was estimated separately before treatment began (knet_no_drug, where it would
take a net positive value) and during treatment (knet_with_drug, where it would take a net negative value).
During therapy, knet is a ﬁrst-order elimination rate constant, which can be interpreted as the slope of the
modeled line ﬁt through the logarithmic transform of the data (with the units of these data being
week1). Parameter estimation was carried out with nonlinear regression using the nonlinear least-
squares optimization function lsqnonlin as part of the pracma package in the R statistical software
language with an objective function weighted by 1/(predicted value)2. The standard errors of the
parameter estimates were calculated using the method described previously (31), with the Jacobian of
the model parameter sensitivities being estimated using a numerical central difference method. For data
analysis purposes, rather than using the average for the data at each time point, the data sets for multiple
individual subject animals were treated as a naive pool (32). The signiﬁcance of the differences between
model parameter estimates under different therapies was examined with pairwise Z-tests incorporating
a Bonferroni correction of 3, where P values of 0.017 were considered signiﬁcant. The signiﬁcance of
the differences between the relapse rates was determined with pairwise Fisher’s exact tests, also with a
Bonferroni correction of 3, with P values of 0.017 being considered signiﬁcant.
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